公开(公告)号：US20240238264A1

公开(公告)日：2024-07-18

申请号：US18406825

申请日：2024-01-08

申请人： Washington University ,  Disarm Therapeutics, Inc.

发明人： Jeffrey MILBRANDT ,  Kow ESSUMAN ,  Yo SASAKI ,  Aaron DIANTONIO ,  Xianrong MAO ,  Rajesh DEVRAJ ,  Raul Eduardo KRAUSS ,  Robert Owen HUGHES

IPC分类号： A61K31/4439 ,  A61K31/047 ,  A61K31/145 ,  A61K31/198 ,  A61K31/41 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/566 ,  A61K31/7048 ,  A61K31/7084 ,  A61K33/243 ,  A61K33/245 ,  A61K33/28 ,  A61K33/30 ,  A61K47/52 ,  A61K47/55 ,  A61P25/28

CPC分类号： A61K31/4439 ,  A61K31/047 ,  A61K31/145 ,  A61K31/198 ,  A61K31/41 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/566 ,  A61K31/7048 ,  A61K31/7084 ,  A61K33/243 ,  A61K33/245 ,  A61K33/28 ,  A61K33/30 ,  A61K47/52 ,  A61K47/55 ,  A61P25/28

摘要： The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

公开(公告)号：US11707498B2

公开(公告)日：2023-07-25

申请号：US16212935

申请日：2018-12-07

申请人： StellaLife, Inc.

发明人： Walter Tatch

IPC分类号： A61K36/714 ,  A61K36/28 ,  A61K36/75 ,  A61K36/56 ,  A61K41/00 ,  A61K45/06 ,  A61K36/68 ,  A61K35/618 ,  A61K33/28

CPC分类号： A61K36/714 ,  A61K33/28 ,  A61K35/618 ,  A61K36/28 ,  A61K36/56 ,  A61K36/68 ,  A61K36/75 ,  A61K41/0004 ,  A61K45/06 ,  A61K36/28 ,  A61K2300/00 ,  A61K36/714 ,  A61K2300/00 ,  A61K36/75 ,  A61K2300/00 ,  A61K36/56 ,  A61K2300/00 ,  A61K36/68 ,  A61K2300/00 ,  A61K35/618 ,  A61K2300/00

摘要： Homeopathic spray, gel, and rinse compositions containing tinctures of Arnica montana, Calendula officinalis, Chamomilla, Ignatia amara, Echinacea purpurea and/or Echinacea angustifolia are disclosed, along with homeopathic compositions containing tinctures of Calendula officinalis, Echinacea purpurea, Plantago major, and Azadirachta indica. Methods of using, and kits containing, the homeopathic spray, gel, rinse and other compositions for maintaining oral care and reducing inflammation, pain, and bruising after oral surgery are provided.

公开(公告)号：US11679125B1

公开(公告)日：2023-06-20

申请号：US18067605

申请日：2022-12-16

申请人： EXELA PHARMA SCIENCES, LLC

发明人： John Maloney ,  Aruna Koganti ,  Phanesh Koneru

IPC分类号： A61K33/08 ,  A61K33/06 ,  A23L33/16 ,  A61K31/191 ,  A61K9/00 ,  A61K31/405 ,  A61K31/095 ,  A23L33/175 ,  A61K31/198 ,  A61K31/4172 ,  A61K31/401 ,  A61K33/28 ,  A61K33/241 ,  A61K33/36 ,  A61K33/00 ,  A61K47/02 ,  A61J1/14

CPC分类号： A61K33/06 ,  A23L33/16 ,  A23L33/175 ,  A61K9/0029 ,  A61K31/095 ,  A61K31/191 ,  A61K31/198 ,  A61K31/401 ,  A61K31/405 ,  A61K31/4172 ,  A61K33/00 ,  A61K33/241 ,  A61K33/28 ,  A61K33/36 ,  A61K47/02 ,  A23V2002/00 ,  A61J1/1412

摘要： The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

公开(公告)号：US11123414B2

公开(公告)日：2021-09-21

申请号：US15853562

申请日：2017-12-22

申请人： PRODUITS NATURASENSE INC.

发明人： Samuel Glen ,  Barbara J. Johnston ,  Lynda Therrien Berthiaume ,  Molly Sharma

IPC分类号： A61K38/54 ,  A61K47/26 ,  A61K36/45 ,  A61K36/88 ,  A61K36/30 ,  A61K36/28 ,  A61K36/81 ,  A61K36/185 ,  A61K33/28 ,  A61K36/23 ,  A61K36/714 ,  A61K33/04 ,  A61K47/44 ,  A61K47/10 ,  A61K47/12 ,  A61K36/75 ,  A61K9/06 ,  A61K9/00 ,  A61K41/00 ,  A61K47/42 ,  A61K36/886 ,  A61K47/14

摘要： The present document describes a non-carcinogenic cream for delivery of active ingredients in the dermis of a patient, which comprises a synergistic combination of about 10 to 25% of oil about 10 to 25% of emulsifier about 1 to 12% of preservative about 45 to 80% of water, aloe water or hamamelis water; and about 1 to 25% of at least one homeopathic active ingredient chosen from pancreatinum, ruta graveolens, ledum palustre, colchicum autumnale, symphytum officinalis, salix alba, harpagophytum, bryonia, capsicum, rhododendron, benzoic acid, salicilicum acid, arnica montana, atropa belladonna, achillea millefolium, hamamelis, agaricus, aesculus, mercurius solubilis, mercurius iodatus, conium maculatum, echinacea angustifolia, echinacea purpurea, scrofularia nosada, pulsatilla, aconitum napellus, hypericum perforatum, bellis perennis, matricaria chamomilla, ranunculus, phytolacca decandra, dulcamara solanum, kalmia, actea racemosa, spigelia, gnaphalium, calendula officinalis, hepar sulphuris, somniferrum, calcarea fluorica, thiosinaminum, hydrastis, arctium lappa, gallium aparine, urtica urens, aloe, graphite, petroleum or a synergistic combination thereof.

公开(公告)号：US10918662B1

公开(公告)日：2021-02-16

申请号：US16850973

申请日：2020-04-16

申请人： Exela Pharma Sciences, LLC

发明人： John Maloney ,  Aruna Koganti ,  Phanesh Koneru

IPC分类号： A61K33/06 ,  A61K31/095 ,  A61K31/401 ,  A61K31/405 ,  A61K47/02 ,  A61K33/241 ,  A61K9/00 ,  A61K33/36 ,  A61K33/00 ,  A23L33/175 ,  A61K33/28 ,  A23L33/16 ,  A61K31/198 ,  A61K31/4172 ,  A61K31/191 ,  A61J1/14

摘要： The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

公开(公告)号：US20190105364A1

公开(公告)日：2019-04-11

申请号：US16212935

申请日：2018-12-07

申请人： StellaLife, Inc.

发明人： Walter Tatch

IPC分类号： A61K36/714 ,  A61K36/56 ,  A61K41/00 ,  A61K36/28 ,  A61K35/618 ,  A61K33/28 ,  A61K36/75 ,  A61K45/06 ,  A61K36/68

摘要： Methods of maintaining general oral care as well as reducing inflammation, pain, and bruising after oral surgery with a homeopathic recovery kit are disclosed.

公开(公告)号：US20170136050A1

公开(公告)日：2017-05-18

申请号：US15357230

申请日：2016-11-21

申请人： CORE INTELLECTUAL PROPERTIES HOLDINGS, LLC

发明人： Roger Blotsky ,  Krys Bojanowski ,  Ramon Figueroa ,  Reynold Dominguez

IPC分类号： A61K31/704 ,  A61K33/20 ,  A61K33/42 ,  A61K33/00 ,  A61K33/24 ,  A61K33/36 ,  A61K33/22 ,  A61K33/34 ,  A61K33/16 ,  A61K33/18 ,  A61K33/26 ,  A61K33/28 ,  A61K33/30 ,  A61K33/38 ,  A61K33/44 ,  A61K33/04 ,  A23L2/52 ,  A23L27/30 ,  A23L33/105 ,  A23L33/16 ,  A61K33/06

CPC分类号： A61K31/704 ,  A23K20/121 ,  A23L2/52 ,  A23L2/60 ,  A23L27/36 ,  A23L33/105 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/7042 ,  A61K33/00 ,  A61K33/04 ,  A61K33/06 ,  A61K33/14 ,  A61K33/16 ,  A61K33/18 ,  A61K33/20 ,  A61K33/22 ,  A61K33/24 ,  A61K33/245 ,  A61K33/26 ,  A61K33/28 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K33/36 ,  A61K33/38 ,  A61K33/40 ,  A61K33/42 ,  A61K33/44 ,  A61K35/08 ,  A61K2300/00

摘要： The present invention comprises compositions that provide anti-glycation activity comprising a mineral extract composition or a mogroside/mineral extract composition or a mogroside composition. Such compositions are useful for methods of preventing, treating and inhibiting the effects of glycation in the body. The methods of the present invention comprise use of anti-glycation composition for the treatment and prevention of glycation related conditions including diabetes, atherosclerosis, arthritis, mental conditions and vision impairment.

公开(公告)号：US20130216574A1

公开(公告)日：2013-08-22

申请号：US13400122

申请日：2012-02-20

申请人： James Liu

发明人： James Liu

IPC分类号： A61K39/145 ,  A61K33/04 ,  A61K33/28 ,  A61K36/28 ,  A61K36/61 ,  A61K33/42 ,  A61K33/44 ,  A61K33/24 ,  A61P29/00 ,  A61P31/00 ,  A61P37/08 ,  A61P11/00 ,  A61P11/06 ,  A61P11/02 ,  A61P37/04 ,  A61P31/16 ,  A61K31/167 ,  A61K36/714

CPC分类号： A61K41/0004 ,  A61K9/0043 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K45/06

摘要： The present invention discloses a unique kit for providing a combinational therapeutic product comprising a medical device and a pharmaceutical composition to treat mammal diseases. The medical device is to meet these unmet needs of cleansing out these harmful substances, such as viruses, multiple drug resistant bacteria, fungi, pollen, dusts, or excessive mucus. The pharmaceutical composition adds the required functions of anti-inflammatory, anti-allergy, anti-cancer, promoting membrane healing or immunomodulating, to have the added effect of the medical device. The method of using the combinational product is also disclosed. The new product can be used to prevent and treat a variety of diseases, such as common cold, drug resistant influenza, sinusitis, post nasal drip, virus-triggered asthma, or chronic obstructive pulmonary disease. In addition, the new kit and the process of use are safe and cost effective.

摘要翻译： 本发明公开了一种用于提供包含治疗哺乳动物疾病的医疗装置和药物组合物的组合治疗产品的独特试剂盒。 医疗器械应满足清洁这些有害物质如病毒，多种耐药细菌，真菌，花粉，灰尘或过多粘液等未满足的需求。 药物组合物增加抗炎，抗过敏，抗癌，促进膜愈合或免疫调节的功能，具有医疗器械的附加效果。 还公开了使用组合产品的方法。 新产品可用于预防和治疗各种疾病，如感冒，耐药性流感，鼻窦炎，鼻后滴，病毒引发的哮喘或慢性阻塞性肺疾病。 此外，新套件和使用过程是安全且具有成本效益的。

公开(公告)号：US20120009253A1

公开(公告)日：2012-01-12

申请号：US13240232

申请日：2011-09-22

申请人： Wolfgang Fleischer ,  Karen Reimer

发明人： Wolfgang Fleischer ,  Karen Reimer

IPC分类号： A61K9/127 ,  A61K9/14 ,  A61K31/80 ,  A61K31/164 ,  A61K31/4166 ,  A61K31/015 ,  A61K33/28 ,  A61K31/05 ,  A61K33/18 ,  A61K31/055 ,  A61K33/38 ,  A61K31/47 ,  A61K31/473 ,  A61K31/505 ,  A61P31/00 ,  A61P11/00 ,  A61P23/00 ,  A61K9/20 ,  A61P31/18 ,  A61P31/06 ,  A61P31/04 ,  A61K9/00 ,  B82Y5/00

CPC分类号： A61K9/127 ,  Y02A50/465

摘要： Use of an anti-inflammatory agent such as povidone iodine for the preparation of a pharmaceutical composition for the treatment of diseases of the lower respiratory tract which are susceptible to the administration of such agents.

摘要翻译： 使用抗炎剂如聚维酮碘用于制备用于治疗易于施用此类药剂的下呼吸道疾病的药物组合物。

公开(公告)号：US20090175957A1

公开(公告)日：2009-07-09

申请号：US12299110

申请日：2007-04-26

申请人： Earle John Loxton ,  Rudolph Johannes Malan ,  Stefan Coetzee

发明人： Earle John Loxton ,  Rudolph Johannes Malan ,  Stefan Coetzee

IPC分类号： A61K33/24 ,  A61K33/38 ,  A61K33/06 ,  A61K33/28 ,  A61K33/36 ,  A61K31/70

CPC分类号： A61K31/352 ,  A61K31/70 ,  A61K33/06 ,  A61K33/24 ,  A61K33/28 ,  A61K33/36 ,  A61K33/38 ,  A61K45/06 ,  C08B37/0006 ,  A61K2300/00

摘要： A composition is provided which comprises an acidic component, generally fulvic acid, having a molecular weight not exceeding 20,000 Daltons and a low content of the elements aluminium, mercury, cadmium, chromium and lead. The acidic component is preferably carbohydrate derived and preferably using a wet oxidation process.

摘要翻译： 提供了一种组合物，其包含分子量不超过20,000道尔顿的酸性组分，通常为富里酸，元素铝，汞，镉，铬和铅的含量低。 酸性组分优选为衍生碳水化合物，优选使用湿氧化方法。